Akebia Therapeutics (STU:AX9) GF Value Rank: 7 (As of Jul. 15, 2026) — 40% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AX9 Akebia Therapeutics Inc STU:AX9
51 GF Score
Price €1.22
GF Value €1.12
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics GF Value Rank?

Akebia Therapeutics STU:AX9 +1.87% 51 GF Value Rank is 7 as of Jul. 15, 2026, which is 40% above its 10-year median of 5.00. GuruFocus rates STU:AX9 with a GF Score™ of 51/100 and a GF Value™ of €1.12 (Fairly Valued). The stock has 5 warning signs investors should review.

Akebia Therapeutics has the GF Value Rank of 7.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Akebia Therapeutics GF Value Rank Related Terms


STU:AX9 vs TKNO, ORGO, SIGA: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's GF Value Rank falls into.


STU:AX9
51GF Score
Akebia Therapeutics Inc STU:AX9
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 7 mean?
Akebia Therapeutics (STU:AX9) has a GF Value Rank of 7 as of Jul. 15, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Akebia Therapeutics and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, Akebia Therapeutics' GF Value Rank has ranged from 1.00 to 10.00.
Is Akebia Therapeutics' GF Value Rank too high?
Akebia Therapeutics' current GF Value Rank of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' GF Value Rank compare to TKNO and ORGO?
Akebia Therapeutics' GF Value Rank of 7 can be compared against companies in the Drug Manufacturers industry. Historically, Akebia Therapeutics' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current GF Value Rank is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.12, compared to a current price of €1.22 — trading 9.2% above its estimated fair value. The current GF Value Rank is 7, which is 40% above median its 10-year median of 5.00. Akebia Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current GF Value Rank is 7 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of €1.22 is trading 9.2% above its estimated GF Value™ of €1.12. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • GF Value Rank: 7 (40% above median its 10-year median of 5.00)
  • GF Value™: €1.12 vs. price of €1.22 (9.2% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score

Get the complete analysis for STU:AX9

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.22
Price
€1.12
GF Value